Quarterly report · Q1
4543.TEDINET S100OZIL
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥197.3bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥703.3bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥171.7bn | 2021-04-01 → 2021-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥30.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥36.2bn | 2021-04-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥29.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥114.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥36.0bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥88.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥27.9bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥27.9bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.58T | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.47T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.34T | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥466.9bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥461.4bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.12T | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥874.0bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥856.7bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.12T | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.01T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥874.0bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥209.6bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥186.7bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥200.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥23.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥141.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥29.9bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥16.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥78.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥21.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥14.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥70.9bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥23.1bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥29.61 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥117.45 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥36.9 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥29.6 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥117.38 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥36.87 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 70.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.7% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.2% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-06-30 | ¥62m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥198m |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥34.5bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥3.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥116.8bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥28.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥46.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥197.3bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥36.1bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-06-30 | ¥64m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥1.6bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥28.3bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥6.0bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥99.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥29.4bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥43.8bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥6.4bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥171.7bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥41.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 562
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYTDDuration | -135000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YTDDuration | -21023000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYTDDuration | -16122000000 | JPY |
| Proceeds from short term borrowings fin cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from short term borrowings fin cf IFRS | CurrentYTDDuration | 648000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -250000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | -297000000 | JPY |
| Redemption of bonds fin cf IFRS | Prior1YTDDuration | -10000000000 | JPY |
| Redemption of bonds fin cf IFRS | CurrentYTDDuration | － | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YTDDuration | -1640000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -1787000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1YTDDuration | -0 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | CurrentYTDDuration | -0 | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -11165000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -13408000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -23056000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -14845000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 151000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 11920000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | -14024000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | 4314000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 200770000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 205251000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 186745000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 209566000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 99568000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 43783000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 28301000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 171652000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | 64000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 171716000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 29368000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 6448000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 5987000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 41805000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -1601000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration | 40203000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -1808000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q1r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -2067000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReportableSegmentsMember | -3875000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReconcilingItemsMember | -37000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration | -3913000000 | JPY |
| Non recurring profit or loss IFRS | Prior1YTDDuration | -56000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 36233000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 248000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 495000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 33000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 36020000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q1r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 116825000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |